Quantifying Early-Stage Lung Adenocarcinoma Progression with a Radiomic Trajectory

1

RadioTrace integrates radiomic and pathological data to quantify progression in early-stage lung adenocarcinoma (esLUAD).
2

The framework effectively predicts tumor phenotypes, including spread through air spaces and lymph node metastasis across multiple cohorts.
3

Survival analyses indicate that RadioTrace serves as an independent prognostic factor, revealing significant survival heterogeneity within the same pathological grade.
4

Genomic and transcriptomic analyses confirm associations between RadioTrace scores and progression-related molecular features.
5

RadioTrace provides a continuous measurement of tumor progression, enhancing diagnostic precision and clinical decision-making for esLUAD.

Npj Digital Medicine

by Zhen-Bin Qiu, Jiaqi Li, Shihua Dou, Qiuchen Meng, Meng-Min Wang, Hong-Ji Li, Chao Zhang, Hongsheng Xie, Ben-Yuan Jiang, Jun-Tao Lin, Jia-Tao Zhang, Fang-Ping Xu, Jin-Hai Yan, Lei Wei, Yi-Long Wu, Haibo Wang, Lin Yang, Xuegong Zhang, Wen-Zhao Zhong
November 17, 2025

1